NCT06407219 Evaluating the Impacts of a Single Session of Robot Assisted Gait Training With a Trexo
| NCT ID | NCT06407219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Physical Disability |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-03-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2022-03-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Early use of robotic gait trainers have shown many benefits, however why these benefits occur and how to maximize them is unknown. There are a few options for how a robotic gait trainer can be used, however, there is not much understanding of how these options impact rehabilitation and compensate for impairments. The investigators aim to evaluate the impacts of as single session of Trexo robotic gait training and the impact of different modes of the Trexo robotic gait trainer. The investigators will evaluate how the different settings impact things like physical activity, walking, brain activity, spasticity, and fatigue. Investigators will arrange for a familiarity and fitting session to start, so that study team members can fit the participant to the Trexo and so that participants can become familiar with the feeling of using the Trexo robotic gait trainer. After the initial fitting sessions, follow up sessions will be completed to evaluate different settings on the Trexo, for example in "endurance" mode (where the robot completes the movements for the participant) and in "strength" mode (where the robot requires some assistance from the participant). Investigators may also test different fitting settings, for example with and without the supportive seat in the Trexo. Only three visits are required (one fitting/familiarity session and two testing sessions), however participants and/or their families may choose to complete more testing sessions if they want to assess other aspects of the training. For example, if the first two testing sessions assessed physical activity, participants and their families may choose to return for further sessions to assess brain activity. The aim of the study is to determine how robot assisted gait training impacts rehabilitation and compensates for impairments, as well as to provide suggestions on how the robotic gait trainer might be improved or modified. This study is exploratory to find out more about how these robotic gait trainers, specifically the Trexo, impacts various aspects of rehabilitation.
Eligibility Criteria
Inclusion Criteria: * Able to fit into the Trexo robotic gait trainer (\<150 lbs., \<5'7"). * Has impaired ability to walk due to a neurological or muscular disorder. Exclusion Criteria: * \>150 lbs. * \>5'6" tall * Medical contraindication to weight bearing (ie. recent orthopedic surgery)
Contact & Investigator
Elizabeth G Condliffe, MD, PhD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT06407219 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, studying Physical Disability. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06407219 currently recruiting?
Yes, NCT06407219 is actively recruiting participants. Contact the research team at poni.lab@ucalgary.ca for enrollment information.
Where is the NCT06407219 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT06407219 clinical trial?
NCT06407219 is sponsored by University of Calgary. The principal investigator is Elizabeth G Condliffe, MD, PhD at University of Calgary. The trial plans to enroll 50 participants.